AI-ECHO Hemodynamic Phenotyping in Septic Shock
AI-ECHO-Based Intelligent Hemodynamic Subtyping and Dynamic Evolution in Septic Shock: A Prospective Observational Cohort Study
This is a prospective, single-center, observational cohort study. The purpose of this study is to investigate the hemodynamic heterogeneity and dynamic evolution patterns in patients with septic shock, using point-of-care echocardiography combined with artificial intelligence technology. The study will enroll 240 adult patients with septic shock admitted to the ICU. Standardized cardiac ultrasound examinations will be performed at multiple time points, and multi-dimensional clinical-echocardiographic data will be collected. An AI-based automatic echocardiographic analysis system will be developed, and unsupervised machine learning will be applied to identify distinct hemodynamic subtypes and their dynamic evolution trajectories. This study aims to provide innovative solutions for individualized and precise hemodynamic management of septic shock.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Background
Septic shock is the most severe stage of sepsis and is associated with mortality as high as 40%-50%. Its pathophysiological core involves profound hemodynamic disturbances resulting from complex interactions among abnormal vascular tone, relative or absolute intravascular volume deficiency, myocardial depression, and microcirculatory dysfunction.
Accumulating evidence has demonstrated substantial heterogeneity in hemodynamic profiles among patients with septic shock, including hyperdynamic states, left ventricular systolic or diastolic dysfunction, right ventricular dysfunction, and various combined phenotypes. The traditional binary classification of "warm shock" versus "cold shock" is too simplistic to capture this complexity. Such heterogeneity may partly explain why uniform treatment strategies, such as early goal-directed therapy, have yielded inconsistent results and may cause iatrogenic harm in certain subgroups.
Echocardiography has become an important tool for hemodynamic assessment in the intensive care unit (ICU). It enables noninvasive, real-time evaluation of cardiac structure and function, including left ventricular ejection fraction (LVEF), global longitudinal strain (GLS), right ventricular function, diastolic function, cardiac output, and volume status. However, its clinical utility is limited by:
- High operator dependency and interobserver variability;
- Time-consuming post-processing and interpretation;
- Difficulty in performing frequent dynamic assessments in busy ICU settings; and
- Limited integrated analysis of multiple parameters over time.
Recent advances in artificial intelligence (AI), particularly deep learning, have shown considerable promise in medical image analysis. In echocardiography, AI has demonstrated promising performance in view classification, cardiac structure segmentation, and automated measurement of functional parameters. Meanwhile, unsupervised machine learning methods provide potential approaches for identifying disease subtypes from high-dimensional clinical data.
Building on the established "Guangzhou Sepsis Cohort" and prior research experience in AI-assisted critical care medicine, this study will integrate AI and echocardiography to systematically characterize hemodynamic phenotypes and their dynamic evolution in patients with septic shock.
Study Design
This is a prospective, single-center, observational cohort study. A total of 360 adults with septic shock admitted to the ICU of The Second Affiliated Hospital of Guangzhou Medical University are anticipated to be consecutively enrolled.
Echocardiographic examinations will be performed on Day 1, Day 3, and Day 7 after enrollment. Clinical data, laboratory measurements, treatment information, and clinical outcomes will be collected according to the study protocol.
At each echocardiographic time point, standardized point-of-care echocardiography will be performed using the same model of ultrasound system and a phased-array transducer. Cine loops of the apical four-chamber, two-chamber, and three-chamber views will be acquired for at least three cardiac cycles. Additional Doppler, M-mode, right ventricular-focused, left ventricular outflow tract, and inferior vena cava recordings will be acquired as required for the prespecified echocardiographic measurements and as detailed in the imaging manual. All images will be stored in de-identified DICOM format using a unique study identification code.
AI-derived measurements will be used for research purposes only and will not guide clinical management. Clinical treatment will be determined by the treating clinical team and will not be assigned by the study.
Clinical data collected at or near the echocardiographic examinations will include vital signs, laboratory measurements, fluid balance, vasopressor dosage, and other treatment information. Blood samples will be collected on Day 1, Day 3, and Day 7 for targeted proteomic and metabolomic analyses, as specified in the study protocol.
Study Objectives
Primary Objective:
To identify and characterize distinct hemodynamic subtypes of septic shock using an unsupervised Gaussian mixture model based on prespecified multidimensional echocardiographic parameters.
Secondary Objectives:
• Longitudinal changes and dynamic evolution of hemodynamic status within 7 days after enrollment;
- Associations of hemodynamic phenotypes with clinical severity and clinical outcomes;
- Agreement between AI-derived and blinded expert echocardiographic measurements;
- Exploratory associations of targeted proteomic and metabolomic profiles with hemodynamic phenotypes; and
- Exploratory development and internal validation of an early-warning model for 28-day all-cause mortality.
Study Population
Adults (≥18 years) with septic shock, diagnosed according to the Sepsis-3 criteria, who meet the eligibility criteria listed in the Eligibility section will be consecutively enrolled from the ICU of The Second Affiliated Hospital of Guangzhou Medical University. Eligible participants must have an expected ICU stay of at least 72 hours, and written informed consent must be obtained from the patient or a legally authorized representative.
Outcome Measures
Primary Outcome:
Hemodynamic subtypes identified using an unsupervised Gaussian mixture model based on prespecified multidimensional echocardiographic parameters collected within 7 days after enrollment.
Secondary Outcomes:
- Agreement between AI-derived echocardiographic measurements and blinded expert reference measurements, evaluated using intraclass correlation coefficients and Bland-Altman analyses;
- Associations between hemodynamic subtypes and 28-day mortality;
- Associations between hemodynamic subtypes and organ failure severity, as assessed by the Sequential Organ Failure Assessment (SOFA) score;
- Duration of vasopressor use; and
- ICU and hospital lengths of stay.
Statistical Analysis
Sample Size Considerations: The planned enrollment of 240 participants is based on the anticipated number of eligible septic shock admissions during the recruitment period, expected consent and follow-up completion, and study feasibility. The target sample size is intended to provide an adequate dataset for exploratory hemodynamic phenotyping and longitudinal echocardiographic analyses. As the primary objective is exploratory hemodynamic phenotyping using unsupervised analysis, no formal hypothesis-based power calculation was performed. Analyses of clinical outcomes, multi-omics profiles, and early-warning models will be considered exploratory, and model complexity will be limited according to the effective sample size and number of observed events.
Continuous variables will be summarized as mean ± standard deviation or median with interquartile range, as appropriate. Categorical variables will be summarized as frequencies and percentages.
An unsupervised Gaussian mixture model will be applied to identify hemodynamic subtypes based on prespecified echocardiographic parameters. Clinical characteristics, treatment information, and outcomes will be compared among the identified subtypes.
Agreement between AI-derived measurements and blinded expert reference measurements will be evaluated using intraclass correlation coefficients and Bland-Altman analyses. Targeted proteomic and metabolomic analyses will evaluate associations between protein or metabolite abundances and hemodynamic phenotype membership using methods appropriate for high-dimensional data. Where applicable, the false discovery rate will be used to account for multiple comparisons. These analyses will be considered exploratory.
An exploratory early-warning model for 28-day all-cause mortality will be developed using prespecified candidate predictors. Model discrimination will be assessed using the area under the receiver operating characteristic curve, and calibration will be evaluated using calibration plots and calibration statistics. Internal validation will be performed using bootstrap resampling or cross-validation. The number of candidate predictors and model complexity will be limited according to the number of observed events to reduce the risk of overfitting.
Multivariable logistic regression or Cox proportional hazards models will be constructed, as appropriate, to explore factors associated with adverse clinical outcomes. Repeated measurements and missing data will be addressed according to the prespecified statistical analysis plan.
Statistical analyses will be performed using SPSS, R, and Python. A two-sided P value <0.05 will be considered statistically significant, with exploratory analyses interpreted accordingly.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Weiyan Chen, MD, PhD
- Phone Number: +86 13751845652
- Email: sam11124@163.com
Study Contact Backup
- Name: Lili Tao, MD
- Phone Number: +86 020-34153246
- Email: taollicu@163.com
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 511436
- The Second Affiliated Hospital of Guangzhou Medical University
-
Contact:
- Weiyan Chen, MD, PhD
- Phone Number: +86 13751845652
- Email: sam11124@163.com
-
Contact:
- Lili, Tao
- Phone Number: +86 020-34153246
- Email: taollicu@163.com
-
Principal Investigator:
- Weiyan Chen, MD, PhD
-
Sub-Investigator:
- Lili Tao, MD
-
Sub-Investigator:
- Sihong Xie, PhD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
This is a prospective observational cohort study enrolling adult patients with septic shock admitted to the ICU. The study aims to construct a multi-dimensional clinical-echocardiographic database, develop an AI-based automatic echocardiographic analysis system, identify hemodynamic subtypes using unsupervised machine learning, and reveal the dynamic evolution patterns of hemodynamics in septic shock.
Description
Inclusion Criteria:
- Age ≥18 years.
- Confirmed diagnosis of septic shock according to the Sepsis-3 criteria.
- Expected ICU stay of at least 72 hours.
- Written informed consent obtained from the patient or legally authorized representative.
Exclusion Criteria:
Patients meeting any of the following criteria will be excluded:
- Severe chronic heart disease, such as severe valvular heart disease or chronic heart failure with left ventricular ejection fraction (LVEF) <30%.
- Acute coronary syndrome.
- Status post cardiac surgery.
- Pregnancy.
- Inability to obtain high-quality echocardiographic images at screening.
Study Plan
How is the study designed?
Design Details
- Observational Models: COHORT
- Time Perspectives: PROSPECTIVE
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Septic Shock Patients
Adults with septic shock admitted to the intensive care unit who meet the eligibility criteria listed in the Eligibility section. Participants will undergo standardized point-of-care echocardiography on Day 1, Day 3, and Day 7 after enrollment, together with clinical data and blood sample collection as specified in the study protocol. Clinical management will be determined by the treating clinical team and will not be assigned by the study. AI-derived echocardiographic measurements will be used for research purposes only and will not guide clinical management. |
Standardized point-of-care echocardiography will be performed on Day 1, Day 3, and Day 7 after enrollment. Images will be acquired according to the imaging manual and stored in de-identified DICOM format using a unique study identification code. Echocardiographic parameters will be used for hemodynamic phenotyping and assessment of changes over time. |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Echocardiography-Derived Hemodynamic Phenotypes in Adults With Septic Shock
Time Frame: Within 7 days after enrollment
|
Identification and characterization of distinct hemodynamic phenotypes in adults with septic shock using unsupervised analysis of prespecified multidimensional echocardiographic parameters. The parameters may include measures of left ventricular systolic and diastolic function, right ventricular function, cardiac output or flow, and inferior vena cava dynamics, depending on data availability and image quality. The number and characteristics of the identified phenotypes will be determined using prespecified model selection and evaluation procedures. |
Within 7 days after enrollment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Longitudinal Changes and Dynamic Evolution of Hemodynamic Status
Time Frame: Day 1, Day 3, and Day 7 after enrollment.
|
Serial changes in echocardiographic parameters and transitions among hemodynamic phenotypes will be evaluated during follow-up. |
Day 1, Day 3, and Day 7 after enrollment.
|
|
Associations Between Hemodynamic Phenotypes and Clinical Severity and Outcomes
Time Frame: Within 7 days after enrollment for severity measures; up to 28 days or during the index hospitalization for clinical outcomes.
|
Associations of hemodynamic phenotypes with SOFA score, blood lactate, 28-day all-cause mortality, vasopressor duration, and ICU and hospital length of stay will be evaluated. |
Within 7 days after enrollment for severity measures; up to 28 days or during the index hospitalization for clinical outcomes.
|
|
Agreement Between AI-Derived and Blinded Expert Echocardiographic Measurements
Time Frame: Day 1, Day 3, and Day 7 after enrollment.
|
Agreement for prespecified echocardiographic parameters will be evaluated using intraclass correlation coefficients and Bland-Altman analyses. |
Day 1, Day 3, and Day 7 after enrollment.
|
|
Associations Between Molecular Profiles and Hemodynamic Phenotypes
Time Frame: Day 1, Day 3, and Day 7 after enrollment.
|
Exploratory associations of targeted proteomic and metabolomic profiles with hemodynamic phenotypes will be evaluated. |
Day 1, Day 3, and Day 7 after enrollment.
|
|
Exploratory Early-Warning Model for 28-Day All-Cause Mortality
Time Frame: Predictors within 7 days; mortality through 28 days after enrollment.
|
An exploratory model will be developed and internally validated using clinical and echocardiographic data. |
Predictors within 7 days; mortality through 28 days after enrollment.
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Weiyan Chen, MD, PhD, Second Affiliated Hospital of Guangzhou Medical University
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- AI-ECHO-SS-2025-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.